Sven Wehrwein
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Proto Labs to Host Q3 2026 Earnings Call. Proto Labs has announced a conference call to discuss its third-quarter 2026 financial results. This upcoming event will provide investors with the latest update on the company’s performance and outlook. The stock currently trades within a wide 52-week range, reflecting recent volatility.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Stifel Keeps Hold Rating on SPS Commerce, Up Target to $85. Stifel has kept its hold rating on SPS Commerce while lifting its price target to $85. The new target sits above the current consensus average of $75.45 and near the top of the 52‑week range. The rating suggests the brokerage sees no immediate upside or downside. The stock is trading with an RSI of 57.3 and a revenue‑price divergence signal over the past year.
Transaction History
| ATRC | ▲ Buy | Option Exercise | 25,000 | $499K | 7/28/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 25,000 | $946K | 7/28/2026 | View on chart |
| PRLB | ▼ Sell | Open Market | 1,500 | $115K | 6/2/2026 | View on chart |
| PRLB | ▼ Sell | Open Market | 500 | $39K | 6/2/2026 | View on chart |
| PRLB | ▲ Buy | Grant | 2,210 | $0 | 5/19/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 6,144 | $0 | 5/18/2026 | View on chart |
| ATRC | ▲ Buy | Option Exercise | 4,967 | $99K | 11/25/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 4,967 | $189K | 11/25/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 5,033 | $188K | 11/24/2025 | View on chart |
| ATRC | ▲ Buy | Option Exercise | 5,033 | $100K | 11/24/2025 | View on chart |
| ATRC | ▲ Buy | Option Exercise | 5,000 | $100K | 8/22/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 5,000 | $185K | 8/22/2025 | View on chart |
| ATRC | ▲ Buy | Option Exercise | 5,000 | $100K | 8/19/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 5,000 | $180K | 8/19/2025 | View on chart |
| PRLB | ▲ Buy | Grant | 3,939 | $0 | 5/23/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 5,401 | $0 | 5/19/2025 | View on chart |
| SPSC | ▲ Buy | Grant | 1,310 | $0 | 5/13/2025 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 2,000 | $187K | 8/9/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,058 | $212K | 8/9/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 400 | $81K | 8/9/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 542 | $110K | 8/9/2024 | View on chart |
| PRLB | ▲ Buy | Grant | 4,701 | $0 | 5/23/2024 | View on chart |
| SPSC | ▲ Buy | Grant | 465 | $0 | 5/16/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 7,788 | $0 | 5/13/2024 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 768 | $45K | 2/15/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 768 | $149K | 2/15/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,640 | $325K | 2/15/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 800 | $155K | 2/14/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 842 | $164K | 2/14/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 400 | $78K | 2/14/2024 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 3,000 | $177K | 2/14/2024 | View on chart |
| SPSC | ▼ Sell | Open Market | 958 | $184K | 2/14/2024 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 500 | $30K | 11/2/2023 | View on chart |
| SPSC | ▼ Sell | Open Market | 500 | $82K | 11/2/2023 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 732 | $38K | 11/1/2023 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 268 | $16K | 11/1/2023 | View on chart |
| SPSC | ▼ Sell | Open Market | 880 | $141K | 11/1/2023 | View on chart |
| SPSC | ▼ Sell | Open Market | 120 | $19K | 11/1/2023 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,000 | $170K | 8/11/2023 | View on chart |
| SPSC | ▲ Buy | Grant | 118 | $0 | 8/3/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 3,186 | $0 | 5/25/2023 | View on chart |
| PRLB | ▲ Buy | Grant | 4,513 | $0 | 5/17/2023 | View on chart |
| SPSC | ▲ Buy | Grant | 585 | $0 | 5/12/2023 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 1,000 | $52K | 3/14/2023 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,000 | $145K | 3/14/2023 | View on chart |
| PRLB | ▲ Buy | Grant | 3,236 | $0 | 8/30/2022 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 1,000 | $52K | 8/15/2022 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,000 | $133K | 8/15/2022 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 1,000 | $52K | 8/5/2022 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,000 | $131K | 8/5/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 3,564 | $0 | 5/25/2022 | View on chart |
| PRLB | ▲ Buy | Grant | 3,236 | $0 | 5/18/2022 | View on chart |
| SPSC | ▲ Buy | Grant | 838 | $0 | 5/17/2022 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 1,100 | $57K | 11/18/2021 | View on chart |
| SPSC | ▼ Sell | Open Market | 1,100 | $165K | 11/18/2021 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 900 | $47K | 11/17/2021 | View on chart |
| SPSC | ▼ Sell | Open Market | 900 | $135K | 11/17/2021 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 792 | $21K | 11/16/2021 | View on chart |
| SPSC | ▲ Buy | Option Exercise | 1,570 | $58K | 11/16/2021 | View on chart |
| SPSC | ▼ Sell | Open Market | 2,362 | $353K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.